Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Clinical trial NCT04864821 · UNKNOWN

Trial details

NCT number: NCT04864821
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Osteosarcoma Neuroblastoma Gastric Cancer Lung Cancer

Start date: 2021-05-14
Primary completion: 2022-05-14
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.